Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Total Current Liabilities (2016 - 2025)

Historic Total Current Liabilities for Akebia Therapeutics (AKBA) over the last 10 years, with Q3 2025 value amounting to $133.4 million.

  • Akebia Therapeutics' Total Current Liabilities rose 10298.44% to $133.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $133.4 million, marking a year-over-year increase of 10298.44%. This contributed to the annual value of $80.9 million for FY2024, which is 1898.07% down from last year.
  • As of Q3 2025, Akebia Therapeutics' Total Current Liabilities stood at $133.4 million, which was up 10298.44% from $118.7 million recorded in Q2 2025.
  • Over the past 5 years, Akebia Therapeutics' Total Current Liabilities peaked at $261.1 million during Q4 2021, and registered a low of $65.7 million during Q3 2024.
  • Its 5-year average for Total Current Liabilities is $138.4 million, with a median of $118.7 million in 2025.
  • Its Total Current Liabilities has fluctuated over the past 5 years, first tumbled by 6609.01% in 2023, then skyrocketed by 10298.44% in 2025.
  • Akebia Therapeutics' Total Current Liabilities (Quarter) stood at $261.1 million in 2021, then plummeted by 50.38% to $129.5 million in 2022, then fell by 22.9% to $99.9 million in 2023, then decreased by 18.98% to $80.9 million in 2024, then skyrocketed by 64.84% to $133.4 million in 2025.
  • Its last three reported values are $133.4 million in Q3 2025, $118.7 million for Q2 2025, and $91.2 million during Q1 2025.